Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 6 de 6
Filtrer
1.
Br J Anaesth ; 132(1): 107-115, 2024 Jan.
Article de Anglais | MEDLINE | ID: mdl-38036323

RÉSUMÉ

BACKGROUND: Residual neuromuscular block is associated with increased patient morbidity. Therefore prevention of residual neuromuscular block is an important component of general anaesthesia where neuromuscular blocking agents are used. Whereas sugammadex improves reversal based on neuromuscular twitch monitoring parameters, there have been no prospective, adequately powered definitive studies demonstrating that sugammadex is also associated with less patient morbidity. METHODS: We performed a systematic review of randomised trials comparing sugammadex with anticholinesterase-based reversal or placebo reversal that reported important patient outcomes beyond the postanaesthesia care unit. RESULTS: We identified 43 articles, including 5839 trial participants. Only one trial reported days alive and out of hospital to 30 days (DAOH-30), which showed that the number of DAOH-30 was similar in those allocated to sugammadex compared with neostigmine-based reversal (25 days [19-27] vs 24 days [21-27], median difference 0.00 [-2.15 to 2.15]). Pooled analyses of data from 16 trials showed an estimated odds ratio (OR) for postoperative pulmonary complications of 0.67 (95% confidence interval 0.47-0.95) with sugammadex use. Pooled analysis showed that pneumonia (eight trials OR 0.51 [0.24-1.01] with sugammadex use), hospital length of stay (23 trials, mean difference -0.31 [-0.84 to 0.22] with sugammadex use), and patient-reported quality of recovery (11 trials, varied depending on metric used) are similar in those allocated to sugammadex vs control. The difference seen in mortality (11 trials, OR 0.39 [0.15-1.01] with sugammadex use) would be considered to be clinically significant and warrants further investigation, however, the rarity of these events precludes drawing definitive conclusions. CONCLUSION: Although few trials reported on DAOH-30 or important patient outcomes, sugammadex is associated with a reduction in postoperative pulmonary complications, however, this might not translate to a difference in hospital length of stay, patient-reported quality of recovery, or mortality. CLINICAL TRIAL REGISTRATION: PROSPERO database (CRD42022325858).


Sujet(s)
Retard de réveil post-anesthésique , Blocage neuromusculaire , Curarisants non dépolarisants , Humains , Sugammadex , Retard de réveil post-anesthésique/prévention et contrôle , Curarisants non dépolarisants/effets indésirables , Néostigmine/usage thérapeutique , Anticholinestérasiques , Complications postopératoires/prévention et contrôle , Anesthésie générale/effets indésirables , Morbidité
2.
Anesthesiol Res Pract ; 2022: 4659795, 2022.
Article de Anglais | MEDLINE | ID: mdl-35844810

RÉSUMÉ

Background: Residual paralysis following anaesthesia is common and can lead to postoperative morbidity. While sugammadex has been shown to be effective in minimising residual paralysis, uncertainty exists as to whether its use reduces any associated morbidity. We designed this trial to determine if the use of sugammadex for the reversal of intraoperative aminosteroid neuromuscular blockade results in improvements in postoperative pulmonary complications, complications in the recovery unit, postoperative nausea and vomiting, and patient satisfaction, when compared to reversal with neostigmine. Methods: A prospective, double-blind, randomised controlled trial in adult patients admitted for surgical operations at two Australian hospitals between December 2018 and March 2019 was performed comparing the reversal of neuromuscular paralysis using sugammadex 2 mg/kg versus neostigmine 50mcg/kg. Statistical analysis of continuous data was performed using two tailed t-tests, with categorical and ordinal data being assessed by chi-squared analysis. Results: The trial was terminated due to a combination of resource constraints and the 2019 novel coronavirus disease (COVID-19) pandemic. Of 51 patients screened, 33 were eligible for participation and 30 subsequently recruited and randomised. All patients received the intended treatment allocated. Data for the primary outcome was obtained in all patients. There was no difference in the rates of postoperative pulmonary complications between the sugammadex and neostigmine groups (0% (0/19) vs 9% (1/11) RR 5.0 (95% CI 0.22-113) p=0.37. There was no difference in any of the secondary outcomes between the groups. Conclusions: The P-PERSoN trial showed no difference in postoperative pulmonary complications between sugammadex and neostigmine based reversal of aminosteroid neuromuscular block, but was underpowered to show any difference due to early trial termination. The randomisation and data collection was feasible. We support the need for an adequately resourced and funded randomised controlled trial to address this important clinical question.

3.
Intensive Care Med ; 35(6): 977-86, 2009 Jun.
Article de Anglais | MEDLINE | ID: mdl-19352621

RÉSUMÉ

PURPOSE: To determine whether corticosteroids reduce the rate of extubation failure in intensive care patients of all age groups. METHODS: Medline, EMBASE, the Cochrane Central Register of Controlled Trials, bibliographies of relevant articles, selected conference abstracts and unpublished trial databases were searched. Randomised clinical trials (RCTs) evaluating corticosteroids for the purpose of preventing extubation failure in mechanically ventilated, critically ill patients of all ages were included. Two authors independently assessed the validity of included studies and extracted data regarding characteristics of the studies and the rates of reintubation and manifestations of laryngeal oedema. RESULTS: Fourteen RCTs including 2,600 participants were included. The mean duration of ventilation prior to attempted extubation ranged from 3 to 21 days. There was a reduction in reintubation with the use of corticosteroids, with a pooled odds ratio (OR) of 0.56 (95% CI; 0.41-0.77, P < 0.0005). The effect of corticosteroids tended to be more pronounced in studies when used at least 12 h prior to attempted extubation (OR 0.41, 95% CI; 0.26-0.64). The results were consistent across neonatal, paediatric and adult populations. There was also a reduction in laryngeal oedema in participants receiving corticosteroids, with a pooled OR of 0.36 (95% CI 0.27-0.49, P < 0.0005). CONCLUSIONS: Corticosteroids reduce laryngeal oedema and importantly reduce the incidence of extubation failure in critically ill patients of all ages.


Sujet(s)
Hormones corticosurrénaliennes/usage thérapeutique , Ventilation artificielle , Insuffisance respiratoire/thérapie , Soins de réanimation , Humains , Soins périopératoires , Essais contrôlés randomisés comme sujet , Reprise du traitement , Échec thérapeutique
5.
Int J Eat Disord ; 34(1): 162-71, 2003 Jul.
Article de Anglais | MEDLINE | ID: mdl-12772182

RÉSUMÉ

OBJECTIVE: The aim of the current study was to compare a new ecologically valid method of body size estimation with an existing, commonly used method. METHOD: The new method uses a "mirror-sized" image and measures perception rather than memory of body size. Fifty-five healthy women participated in the study. RESULTS: Body size estimations with the new method were significantly larger than with the existing method (p <.001). This difference was specific to body size and was not seen for estimation of neutral images. DISCUSSION: The results of the study show that different body size estimations are made with the new more ecologically valid method compared with the existing method. This finding has important implications for research into the factors influencing the perception of body size.


Sujet(s)
Constitution physique , Image du corps , Troubles somatoformes/diagnostic , Adulte , Indice de masse corporelle , Humains , Concept du soi , Troubles somatoformes/psychologie , Enquêtes et questionnaires
6.
Behav Sleep Med ; 1(2): 115-24, 2003.
Article de Anglais | MEDLINE | ID: mdl-15600133

RÉSUMÉ

Patients with insomnia commonly complain that they are unable to get to sleep because of unwanted thoughts and worries. One account given of this excess cognitive activity is that it results from the incomplete processing of daytime stressors and hassles. Previous research has demonstrated the benefits of writing about emotional experiences as a method to facilitate emotional processing. This pilot study tested the hypothesis that writing about worries and concerns, with an emphasis on the expression and processing of emotion, will reduce sleep onset latency among an analogue sample of poor sleepers. Forty-two poor sleepers were randomly allocated to 1 of 3 groups for 3 nights; the instructions for the "problems" writing group emphasized the expression and processing of worries and concerns, the instructions for the "hobbies" writing group emphasized distraction from worries and concerns by writing about hobbies and interests, the "no writing" group were not given a writing task. The "problems" writing group reported shorter sleep onset latency compared to the "no writing" group. The results of this pilot study highlight the potential of research exploring the utility of a Pennebaker-style writing intervention for improving sleep.


Sujet(s)
Troubles de l'endormissement et du maintien du sommeil/psychologie , Troubles de l'endormissement et du maintien du sommeil/thérapie , Écriture , Adulte , Femelle , Humains , Mâle , Troubles de l'endormissement et du maintien du sommeil/diagnostic , Enquêtes et questionnaires
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...